Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).

Under the final rule, pretty much everything in the produce section — whole fruits and vegetables — would be considered healthy, as would other nutrient-rich foods like whole grains, dairy, eggs, ...

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Zealand Pharma expects to start a single phase 3 trial in 2025 to provide confirmatory data for resubmission. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to ...

The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The BLA acceptance was supported by data from the randomized, placebo-controlled phase 2b/3 CLEVER trial as well as interim ...

ACIP recommends extending interval for two-dose series and adding three-dose series in accordance with FDA label ...